Edwards Lifesciences

EWleader

Edwards Lifesciences is the global leader in transcatheter heart valve therapies, particularly TAVR, which has transformed treatment for aortic stenosis from open-heart surgery to a catheter-based procedure.

⇄ Compare

產品與營收

產品營收佔比

營收結構 ($6.4B)

靜態數據（加載即時財務…）

Transcatheter Aortic Valve (60%)

Surgical Structural Heart (15%)

Critical Care (15%)

TMTT (10%)

業務部門構成與主要客戶

產品詳情

TAVR (SAPIEN)60%

Transcatheter aortic valve replacement systems for heart valve disease

TMTT10%

Transcatheter mitral and tricuspid valve therapies in development

Surgical Structural Heart15%

Surgical heart valves and repair products

Critical Care15%

Hemodynamic monitoring and smart recovery technologies

供應鏈關係

競爭對手

Medtronic

CoreValve TAVR system

影響: Primary TAVR competitor

Abbott Laboratories

Structural heart portfolio

影響: Growing competitor in structural heart

Boston Scientific

ACURATE valve

影響: Emerging TAVR competitor

宏觀與市場背景

헬스케어行業新聞

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

近期催化劑

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

AI 分析

點擊「取得 AI 分析」以獲得 Edwards Lifesciences 的 AI 供應鏈分析。

企業資訊

總部

Irvine, California, USA

成立時間

1958

員工人數

20,000+

官網

edwards.com

行業概況 — 헬스케어

行業新聞